Tyrosine kinase inhibitor

Joanna Johnson |

Targeted therapies designed to block the KIT D816V mutation that drives most cases of SM. Includes avapritinib, midostaurin and imatinib.

Your news and information resource for systemic mastocytosis
Part of the Haymarket Medical Network

Rare Disease Companion (RDC) is a network of news and information websites that supports people living with rare diseases. Through accurate, authentic, and compassionate news coverage, feature-length articles, and patient-friendly educational material, RDC provides insights into living with rare diseases at every point along the patient journey.

Copyright © 2026 Haymarket Media, Inc. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions.